معرفی
Alexander H Stegh, PhD, is an Adjunct Professor in the Department of Neurology (Neuro-oncology) at Northwestern University's Feinberg School of Medicine. His research focuses on understanding the genetic program underlying Glioblastoma multiforme (GBM), the most prevalent and malignant form of brain cancer. Dr. Stegh applies cell/molecular biology, oncogenomic and mouse engineering approaches to characterize novel gliomagenic oncogenes and tumor suppressors.
Dr. Stegh received his Biochemistry, Immunology, and Biophysics training at Leibniz University in 1997, followed by his PhD from Leibniz University Hannover in 2000. His educational background forms the foundation for his current research in cancer genetics and neuro-oncology.
Dr. Stegh's research program is dedicated to systematically characterizing novel gliomagenic oncogenes and tumor suppressors in GBM. His work focuses on functionally delineating and validating these pathways toward pharmaceutical opportunities using sophisticated cell culture and animal models. His laboratory has made significant contributions to understanding microRNA regulation in glioblastoma, particularly with miR-182, and has pioneered the use of spherical nucleic acids for targeted gene therapy in brain cancer.
Analysis of Dr. Stegh's publication record reveals a strong focus on translational neuro-oncology research, with emphasis on nanotechnology-based therapeutic approaches for glioblastoma. His work bridges molecular biology, cancer genetics, and nanomedicine to develop novel treatments that can cross the blood-brain barrier.
Scientific Awards and Honors
- Claudia Adams Barr Investigator (2006 - Present)
- NIH K99/R00 Path to Independence Award (2007)
- Zell Foundation Scholar Award (2009)
- Sidney Kimmel Foundation Scholar Award (2010)
- James S. McDonnell 21st Century Award (2011)
- Alliance for Cancer Gene Therapy (ACGT) Young Investigator Award (2013)
- American Cancer Society Research Scholar Award (2014)
- John McNicholas Glioma Scholar Award (2014)
Dr. Stegh serves on the National Cancer Institute (NCI) Glioblastoma Working Group (2015 - Present) and the Scientific Advisory Board of Exicure (2012 - Present). He is an active member of the Society for Neuro-Oncology and the American Association for Cancer Research. His research has been supported by significant grants including the Center for Cancer Nanotechnology Excellence initiative of the National Institutes of Health and the Dixon Translational Research Grants Initiative of the Northwestern Memorial Foundation.
Dr. Stegh is affiliated with the Northwestern University Clinical and Translational Sciences Institute (NUCATS) and the Simpson Querrey Institute for Epigenetics, where he collaborates with multidisciplinary teams to advance brain cancer research and develop novel therapeutic approaches.
